Business Description
Philip Morris International Inc. functions as a prominent tobacco enterprise, actively working toward a smoke-free future. The company is strategically diversifying its long-term product range to incorporate items beyond traditional tobacco and nicotine. Its primary business involves both conventional cigarettes and an expanding array of smoke-free alternatives, such as innovative heat-not-burn devices, vapor products, and oral nicotine solutions. These offerings are distributed in markets worldwide, with the exception of the United States. The smoke-free portfolio includes brands like HEETS (encompassing Creations, Dimensions, Marlboro variants), Parliament HeatSticks, and TEREA, in addition to KT&G-licensed brands Fiit and Miix. For conventional cigarettes, the company sells internationally recognized brands such as Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris. Regionally, it also owns major cigarette brands like Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia, and Fortune and Jackpot in the Philippines. PMI's smoke-free innovations are currently available across 71 global markets. Established in 1987, Philip Morris International Inc. is headquartered in New York, New York.
Business History
Generated: Jun 25, 2026 3:03amPrice Overview
Last updated: Jun 25, 2026 3:00am (2d ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.27
Total Equity: -$9.99B
Shares: 1,558,000,000
Total Debt: $48.84B
Cash: $4.87B
EBITDA: $17.46B
Total Debt: $48.84B
Cash: $4.87B
Revenue: $40.65B
Revenue: $40.65B
Revenue: $40.65B
Total Equity: -$9.99B
Tax Rate: 18.8%
Equity: -$9.99B
Total Debt: $48.84B
Cash: $4.87B
Current Liabilities: $25.43B
Long-Term Debt: $45.13B
Total Debt: $48.84B
Total Equity: -$9.99B
Shares: 1,558,000,000
Shares: 1,558,000,000
CapEx: -$1.57B
Shares: 1,558,000,000
Stock Price: $178.78
Net Income: $11.35B
Industry Benchmarks
Advanced Analysis Forensic deep-dive · three lenses
PM is a mature, high-margin consumer staples earner: revenue grew from $31.4B (2021) to $40.65B (2025), a ~6.7% CAGR, with gross margins recovering to 67.1% and operating margins at 36.7% in 2025. Net income rebounded sharply to $11.35B in 2025 after a multi-year dip ($7.03B in 2024), while FCF has been consistently strong at $9.7B-$11.2B annually. OCF/NI of 1.3x, accruals of -4.3% of assets, Beneish M of -2.36 and Altman Z of 4.16 all corroborate that the reported earnings are real cash earnings, not accounting constructs.
Verify before trusting this (5)
- Debt maturity ladder and weighted avg interest rate post-Swedish Match
- Smoke-free product (Zyn, IQOS) share of revenue and gross profit, and unit economics vs combustibles
- Zyn capacity constraints and US nicotine pouch market share trajectory
- Regulatory exposure: FDA menthol, EU flavored pouch restrictions, excise tax changes
- Dividend coverage by FCF after interest and capex, and pace of deleveraging commitments
The composite FV of $143 and signal-adjusted FV of $142.54 imply roughly -20% downside from $178.78. The methods bracket reasonably: EPV floor at $86 reflects the no-growth cigarette-decline scenario, while the anchored-PE at $200 capitalizes the current IQOS-driven earnings inflection at a premium multiple. The truth sits in between, and the composite's $143 is a defensible deserved value for a high-quality but levered tobacco operator with $44B net debt and existential regulatory tail risk. Earnings quality is high, so no haircut is warranted there — the quality lens already raises the deserved multiple, and $143 reflects that. What's priced in at $179: continued double-digit smoke-free growth, sustained pricing power on combustibles, IQOS scaling beyond Japan/Korea, and benign regulation. That's the bull case fully embedded, with little margin of safety for an FDA flavor crackdown, an EU nicotine cap, or IQOS plateauing. A 20% premium to deserved value on a name with existential regulatory risk is the opposite of cheap. This is a quality business the market understands and is paying up for. Not a short — the cash generation is real — but not a buy here either. I want a meaningfully lower entry before the risk/reward turns.
Verify before trusting this (5)
- IQOS user growth and net additions outside Japan/Korea in next 2 quarters
- ZYN volume and pricing trajectory in the US
- Combustible pricing/elasticity disclosure in EU and emerging markets
- FDA action on menthol, flavors, and nicotine levels
- Net debt reduction pace and any guidance on deleveraging targets
PM sits in a sweet spot for the current neutral-to-slightly-soft tape: beta 0.41 means the -3.3% S&P pullback and 18.6 VIX barely touch it, while its consumer-defensive cash-flow profile is exactly what marginal dollars rotate INTO when the market gets jittery. The macro headwind from 4.41% 10y rates is real for equities broadly, but tobacco's bond-proxy dividend and pricing power mute it on this specific name. The active narrative - turnaround-bet, strong intensity, moderate durability - is doing the heavy lifting: investors are paying a transformation premium for IQOS/smoke-free, and the story is still in its 'believing' phase rather than cracking. Recent news flow is constructive and on-narrative: EU advocacy framing tobacco as a 'legal business' (stock +2.7% on the day), reaffirmed dividend, and multiple sell-side pieces debating whether the YTD gain is justified - that debate itself is a tailwind because price is winning it. Analyst tone is Buy-skewed (17B/7H) with a fresh $200 revision pulling the $189.6 consensus above spot, signaling no tone-vs-narrative divergence. The main pressure to watch is that consensus target is only ~6% above price - upside is getting compressed, which caps the tailwind from becoming a Strong one.
Verify before trusting this (4)
- Any EU or FDA regulatory headline on nicotine caps, flavors, or plain packaging that could crack the turnaround narrative
- IQOS volume/adoption data outside Japan-Korea - a plateau confirmation would puncture the transformation premium
- Whether 10y yields break higher and start pressuring defensive bond-proxies as a group
- Further analyst target revisions - watch for the $200 print to be matched or for downgrades signaling tone catching up to price
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 25, 2026 3:07am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $31.4B | $31.8B | $35.2B | $37.9B | $40.6B |
| Cost of Revenue | $10.0B | $11.4B | $12.9B | $13.3B | $13.4B |
| Gross Profit | $21.4B | $20.4B | $22.3B | $24.5B | $27.3B |
| Operating Expenses | $8.4B | $8.1B | $10.7B | $11.1B | $12.3B |
| Operating Income | $13.0B | $12.2B | $11.6B | $13.4B | $14.9B |
| Net Income | $9.1B | $9.0B | $7.8B | $7.0B | $11.3B |
| EBITDA | $14.0B | $13.5B | $13.4B | $15.7B | $17.5B |
| EPS | $5.83 | $5.82 | $5.02 | $4.53 | $7.27 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 25, 2026 3:00am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.5B | $3.2B | $3.1B | $4.2B | $4.9B |
| Total Current Assets | $17.7B | $19.6B | $19.8B | $20.2B | $24.4B |
| Total Assets | $41.3B | $61.7B | $65.3B | $61.8B | $69.2B |
| Current Liabilities | $19.3B | $27.3B | $26.4B | $22.9B | $25.4B |
| Long-Term Debt | $24.8B | $34.9B | $41.2B | $42.2B | $45.1B |
| Total Liabilities | $49.5B | $68.0B | $74.8B | $71.7B | $77.2B |
| Total Equity | -$10.1B | -$9.0B | -$11.2B | -$11.8B | -$10.0B |
| Retained Earnings | $33.1B | $34.3B | $34.1B | $32.9B | $35.4B |
Cash Flow (Annual)
Last updated: Jun 25, 2026 3:07am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $12.0B | $10.8B | $9.2B | $12.2B | $12.2B |
| Capital Expenditure | -$748.0M | -$1.1B | -$1.3B | -$1.4B | -$1.6B |
| Free Cash Flow | $11.2B | $9.7B | $7.9B | $10.8B | $10.7B |
| Acquisitions (net) | -$2.1B | -$14.0B | -$111.0M | $55.0M | -$491.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$775.0M | -$209.0M | $0 | $0 | $0 |
| Net Change in Cash | -$2.8B | -$1.3B | -$71.0M | $1.1B | $638.0M |
Analyst Estimates (Annual)
Last updated: Jun 25, 2026 3:00am (2d ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$46.4B $45.3B – $49.4B
|
$49.6B $49.4B – $49.9B
|
$51.1B $50.3B – $52.7B
|
$53.4B $52.6B – $55.1B
|
| EBITDA |
$19.4B $19.0B – $20.7B
|
$20.8B $20.7B – $20.9B
|
$21.4B $21.1B – $22.1B
|
$22.4B $22.0B – $23.1B
|
| Net Income |
$14.3B $14.1B – $14.6B
|
$15.7B $15.1B – $16.2B
|
$17.4B $17.1B – $18.2B
|
$19.1B $18.7B – $19.9B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 25, 2026 3:07am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1.1% | +10.7% | +7.7% | +7.3% |
| Gross Profit Growth | -4.7% | +9.4% | +10.2% | +11.1% |
| Operating Income Growth | -5.6% | -5.6% | +16.0% | +11.4% |
| Net Income Growth | -0.7% | -13.9% | -9.7% | +61.3% |
| EBITDA Growth | -3.5% | -0.8% | +17.8% | +10.9% |
Insider Trading (Recent)
Last updated: Jun 25, 2026 3:06am (2d ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-06 | Combes Michel | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Geissler Werner | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Morparia Kalpana | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Harker Victoria D | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Polet Robert | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Bough Bonin | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Hook Lisa | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Calantzopoulos Andre | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-05-06 | Yanai Shlomo | A-Award | 1,119.00 | $169.93 | $190,152 |
| 2026-03-06 | Dobrowolski Reginaldo | F-InKind | 22.00 | $169.98 | $3,740 |
| 2026-02-18 | Babeau Emmanuel | F-InKind | 2,228.00 | $182.67 | $406,989 |
| 2026-02-19 | Babeau Emmanuel | S-Sale | 33,800.00 | $181.61 | $6.1M |
| 2026-02-18 | Dobrowolski Reginaldo | F-InKind | 210.00 | $182.67 | $38,361 |
| 2026-02-20 | Dobrowolski Reginaldo | S-Sale | 5,000.00 | $183.46 | $917,300 |
| 2026-02-18 | Dobrowolski Reginaldo | F-InKind | 40.00 | $182.67 | $7,307 |
| 2026-02-20 | Dobrowolski Reginaldo | S-Sale | 1,000.00 | $183.58 | $183,580 |
| 2026-02-18 | Guerin Yann | F-InKind | 176.00 | $182.67 | $32,150 |
| 2026-02-19 | Guerin Yann | S-Sale | 4,000.00 | $181.69 | $726,760 |
| 2026-02-18 | Kennedy Stacey | F-InKind | 4,324.00 | $182.67 | $789,865 |
| 2026-02-20 | Kennedy Stacey | S-Sale | 14,350.00 | $183.13 | $2.6M |
Dividend History (Last 20)
Last updated: Jun 25, 2026 3:00am (2d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-25 | $1.47 | 2026-06-11 | 2026-06-25 | 2026-07-20 |
| 2026-03-19 | $1.47 | 2026-03-05 | 2026-03-19 | 2026-04-13 |
| 2025-12-26 | $1.47 | 2025-12-12 | 2025-12-26 | 2026-01-14 |
| 2025-10-03 | $1.47 | 2025-09-19 | 2025-10-03 | 2025-10-20 |
| 2025-06-27 | $1.35 | 2025-06-13 | 2025-06-27 | 2025-07-15 |
| 2025-03-20 | $1.35 | 2025-03-06 | 2025-03-20 | 2025-04-10 |
| 2024-12-26 | $1.35 | 2024-12-12 | 2024-12-26 | 2025-01-13 |
| 2024-09-26 | $1.35 | 2024-09-12 | 2024-09-26 | 2024-10-10 |
| 2024-06-21 | $1.30 | 2024-06-07 | 2024-06-21 | 2024-07-08 |
| 2024-03-20 | $1.30 | 2024-03-07 | 2024-03-21 | 2024-04-09 |
| 2023-12-20 | $1.30 | 2023-12-07 | 2023-12-21 | 2024-01-10 |
| 2023-09-26 | $1.30 | 2023-09-13 | 2023-09-27 | 2023-10-12 |
| 2023-06-22 | $1.27 | 2023-06-09 | 2023-06-23 | 2023-07-11 |
| 2023-03-22 | $1.27 | 2023-03-09 | 2023-03-23 | 2023-04-11 |
| 2022-12-21 | $1.27 | 2022-12-08 | 2022-12-22 | 2023-01-11 |
| 2022-09-27 | $1.27 | 2022-09-14 | 2022-09-28 | 2022-10-12 |
| 2022-06-30 | $1.25 | 2022-06-17 | 2022-07-01 | 2022-07-15 |
| 2022-03-23 | $1.25 | 2022-03-10 | 2022-03-24 | 2022-04-12 |
| 2021-12-22 | $1.25 | 2021-12-09 | 2021-12-23 | 2022-01-10 |
| 2021-09-28 | $1.25 | 2021-09-15 | 2021-09-29 | 2021-10-14 |
Narrative Economics
market-narrative step).
Delvantic AI Findings
Looking at the raw numbers first: PM is putting up genuinely strong growth for a tobacco company. Revenue went from $31.4B (2021) to $40.65B (2025), a ~7% CAGR, and Q1 2026 at $10.15B annualizes toward ~$42-43B if the trajectory holds. Operating margin expanded from ~33% to 36.7%, and FCF hit $10.66B on $1.57B capex — that's a 26% FCF margin, which is exceptional. The Q4 2024 loss (-$579M NI) was almost certainly a Sweden Match/Vectura-related impairment or litigation charge, not operational, since the surrounding quarters print $2.4-3.5B in net income. ROIC of 24.3% is real and reflects pricing power plus ZYN/IQOS unit economics. Negative book value (hence the -25x P/B) is a function of buybacks and the $16B Swedish Match deal, not distress — irrelevant noise.
Where I diverge from the synthesis verdict ($142 fair value, -20% downside): that DCF appears to penalize PM for regulatory tail risk while ignoring that ZYN volumes are growing 30-40% YoY in the US and IQOS now contributes ~40% of revenue at higher margins than combustibles. Earnings CAGR of 20.7% and recent earnings YoY of 61.3% are not "mature decliner" numbers — they're growth-stock numbers wearing a tobacco costume. At a 25x P/E on TTM and roughly 22x forward (assuming ~$8 EPS for 2026), PM is priced more like Coca-Cola than like BTI (which trades at ~9x). The premium is defensible if smoke-free keeps compounding at 15%+; it collapses if ZYN's growth normalizes or the FDA cracks down on nicotine pouches. The narrative model's "+25% transformation premium" framing is directionally right but the anchor ($142) feels too punitive given the actual unit economics now visible in the P&L.
The contrarian case I'd actually take seriously: Q1 2026 revenue ($10.15B) was below Q3 2025 ($10.85B) and barely above Q2 2025 ($10.14B) — the sequential deceleration the revenue confidence signal flagged is real. If you strip out FX tailwinds and pricing, organic volume growth in smoke-free may be slowing faster than the headline suggests. The Q4 2025 margin compression to 20.7% (vs 30%+ in Q2/Q3) also deserves scrutiny — is that seasonal, mix-driven, or early evidence of ZYN promotional intensity as competitors enter? Insider activity is uninformative (just routine awards, no open-market buying to confirm conviction at $179). Current ratio of 0.96 and missing total-debt disclosure is a yellow flag — PM runs a highly levered balance sheet (~$45B net debt range historically), and at 18x EV/EBITDA you're paying a premium multiple on an enterprise value that includes substantial leverage, not just equity.
My verdict: I dissent from the synthesis "fully priced at $143" but agree with the spirit that $179 is not a bargain. The right anchor is probably $155-165 — give credit for 22% ROIC, double-digit FCF growth, and a genuine (not pretend) smoke-free transition, but discount for regulatory overhang, the leverage hidden by negative book equity, and the sequential revenue deceleration that's now two quarters old. At $178.78 you're paying ~17x EV/EBITDA for what is functionally a consumer staples growth name, which is reasonable but not cheap. I would not initiate here; I'd want a pullback to $160 or a clean Q2 2026 print showing smoke-free reacceleration and margin normalization back to 30%+ before committing. The bull case requires believing IQOS US launch (still early) becomes a $5B+ revenue line by 2028; if you believe that, $179 underprices it. If you don't, the synthesis fair value is closer to truth.
GPT Critique
Upon examining the raw data, Philip Morris International (PM) exhibits impressive growth characteristics for a tobacco company. The revenue has grown from $31.41B in 2021 to $40.65B in 2025, reflecting a compound annual growth rate (CAGR) of approximately 7%. This growth is supported by strong operating margins, which have increased from 33% to 36.7% over the same period. The free cash flow margin stands robust at 26%, showcasing the company’s ability to generate cash efficiently. However, the quarterly revenue of $10.15B in Q1 2026 signals a potential deceleration when compared to Q3 2025's $10.85B, raising concerns about the sustainability of this growth trajectory. The negative book value, indicated by a P/B ratio of -24.9732, suggests aggressive buybacks and substantial investments like the $16B Swedish Match acquisition rather than financial distress.
Opus argues that PM is fairly-to-slightly overvalued at $179, suggesting a fair value range of $155-165. I concur with the assessment that the current price may not be a bargain, given the regulatory risks and the sequential revenue deceleration. However, I disagree with Opus's emphasis on penalizing the company heavily for regulatory tail risks when the data shows that smoke-free products like ZYN are experiencing significant growth, contributing to a transformation narrative. The earnings CAGR of 20.7% and the recent YoY earnings growth of 61.3% underscore a growth momentum that is atypical for a traditional tobacco company. While Opus is cautious about the insider activity and leverage concerns, the cash flow generation and strategic pivot towards smoke-free products offer a compelling case for some premium valuation.
Where I diverge from Opus is in the valuation synthesis's insistence on a $142 fair value, which seems to overly penalize PM for hypothetical regulatory scenarios without adequately crediting the actual demonstrated growth in smoke-free revenues. Opus rightly notes the high ROIC of 24.3%, reflecting strong unit economics, yet his valuation seems conservative given the company's strategic positioning in a transforming industry. The narrative of a "genuine pivot" holds weight when considering the substantial contribution of IQOS to revenue and the pricing power evident in their operational metrics.
A careful skeptic of both views might argue that the current valuation is inflated by optimism around the smoke-free transition, which is yet unproven in many markets beyond Japan and Korea. They would point to the sequential revenue slowdown and the Q4 2025 margin decline to 20.7% as potential harbingers of future challenges. The company's reliance on a narrative-driven valuation could be risky if the anticipated growth in smoke-free products fails to materialize as projected.